Glenmark, Par settle Zetia patent suit with Merck

WOODCLIFF LAKE, N.J. Glenmark Generics has reached a settlement with Merck over a cholesterol drug, Glenmark partner Par Pharmaceutical said Monday.

The settlement resolves patent litigation related to Glenmark’s challenge to Merck’s patent for Zetia (ezetimibe). Glenmark had sought to launch a generic version of the drug before April 2017, when the patent expires. The settlement will allow Glenmark to launch its version of the drug in December 2016.

Zetia has annual sales of $1.4 billion, according to IMS Health.

Login or Register to post a comment.